Post COVID-19 – Industry Snapshot

Post COVID-19 – Industry Snapshot Long Covid: Research, Policy and Economic Impact Richard Moscicki May 19, 2022

Interventional Clinical Trials to Treat Post COVID-19 There are 141 clinical trials ongoing – 23 sponsored by Industry All Post COVID-19 Clinical Trials by Intervention Type

Biological Drug

7

Biological 39

5

Drug

Combination 1 Other

Industry Sponsored Post COVID-19 Clinical Trials by Intervention Type

9

Combination 0 69

Data as of 4/28/2022 Source: clinicaltrials.gov – search string = "Post Covid" or "Long Covid" Interventional studies

Device

3

C ON F I DE N T IA L

2

1

Lack of pathophysiological mechanism  Few studies to date that explore the possible pathophysiology and risk factors

Post COVID-19: Barriers to therapeutic development

2

Symptoms overlap with other diseases  Pulmonary sequelae, neurologic disorders, mental health disorders, functional mobility impairments, and general and constitutional symptoms, generalized anxiety, functional impairments, fatigue

3

Need for Post COVID-19 diagnostic tests

4

No recognized end points C ON F I DE N T IA L

3

NIH Initiative - RECOVER  Launched in 2021  $1.15 billion in funding over four years to study Post COVID-19  Focus on research and providing unified repositories for data and methods.

https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid

C ON F I DE N T IA L

4

Questions